Humacyte, Inc. (HUMA)
NASDAQ: HUMA · Real-Time Price · USD
0.5516
-0.0094 (-1.68%)
At close: Sep 15, 2026, 4:00 PM EDT
0.5626
+0.0110 (1.99%)
After-hours: Sep 15, 2026, 7:30 PM EDT
Humacyte Revenue
Humacyte had revenue of $406.00K in the quarter ending June 30, 2026, with 34.88% growth. This brings the company's revenue in the last twelve months to $2.12M, up 159.29% year-over-year. In the year 2025, Humacyte had annual revenue of $2.04M.
Revenue (ttm)
$2.12M
Revenue Growth
+159.29%
P/S Ratio
72.25
Revenue / Employee
$11,527
Employees
184
Market Cap
153.23M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 2.04M | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | 1.57M | 302.00K | 23.91% |
| Dec 31, 2021 | 1.26M | -228.00K | -15.29% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Codexis | 77.68M |
| NRx Pharmaceuticals | 3.39M |
| Kazia Therapeutics | 1.27M |
| Molecular Partners AG | 856.30K |
| Spruce Biosciences | 697.00K |
| Outlook Therapeutics | -1.16M |
HUMA News
- 5 days ago - Humacyte to Present at the H.C. Wainwright 28th Annual Global Investment Conference - GlobeNewsWire
- 6 days ago - Humacyte announces FDA extension of expiration dating period for Symvess - TheFly
- 6 days ago - Humacyte Announces FDA Authorization Extending Symvess Shelf Life to 36 Months - GlobeNewsWire
- 11 days ago - Humacyte Investigation Continued: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of Humacyte, Inc. - HUMA - Business Wire
- 22 days ago - Humacyte confirms plans for ATEV supplemental biologic license application - TheFly
- 22 days ago - Humacyte Confirms Plans for ATEV Supplemental BLA Filing for Dialysis Access Following FDA Discussions - GlobeNewsWire
- 27 days ago - Humacyte publishes V007 results in The Lancet Digital Health - TheFly
- 27 days ago - Humacyte Announces Lancet Digital Health Publication of V007 Phase 3 Hemodialysis Access Trial Results - GlobeNewsWire